Trio of studies demonstrate that FLEX Vessel Prep System safely and effectively modifies obstructive plaque to facilitate delivery of definitive therapies
MINNEAPOLIS, Jan. 27, 2021 — VentureMed Group, Inc. (VentureMed), a privately-held medical device innovator, announced today that data from three studies evaluating the use of its FLEX Vessel Prep (VP) System were presented during the virtual Leipzig Interventional Course (LINC) 2021, held Jan. 25 to 29, and are now available on demand.
Among these studies was the CBSET study: Lesion Modification with a Micro-Incision Vessel Preparation System Enhances Balloon-Based Drug Delivery in Complex Porcine Restenotic Lesions.